Search This Blog

Monday, September 30, 2019

Bristol-Myers higher after Opdivo update

Bristol-Myers Squibb (BMY +1.8%) is out with results from a Phase 3 Attraction trial of Opdivo for patients with esophageal cancer.
The company says Opdivo demonstrated a 23% reduction in the risk of death and 2.5-month improvement in median overall survival compared to chemotherapy
BMY management is updating on the results at a Presidential Symposium during the European Society for Medical Oncology 2019 Annual Congress.
Source: Press Release
https://seekingalpha.com/news/3502671-bristol-myers-higher-opdivo-update

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.